SFTPA1 is a potential prognostic biomarker correlated with immune cell infiltration and response to immunotherapy in lung adenocarcinoma
Open Access
- 28 June 2021
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 71 (2) , 399-415
Abstract
Pulmonary surfactant protein A1 (SFTPA1) is a member of the C-type lectin subfamily that plays a critical role in maintaining lung tissue homeostasis and the innate immune response. SFTPA1 disruption can cause several acute or chronic lung diseases, including lung cancer. However, little research has been performed to associate SFTPA1 with immune cell infiltration and the response to immunotherapy in lung cancer. The findings of our study describe the SFTPA1 expression profile in multiple databases and was validated in BALB/c mice, human tumor tissues, and paired normal tissues using an immunohistochemistry assay. High SFTPA1 mRNA expression was associated with a favorable prognosis through a survival analysis in lung adenocarcinoma (LUAD) samples from TCGA. Further GeneOntology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses showed that SFTPA1 was involved in the toll-like receptor signaling pathway. An immune infiltration analysis clarified that high SFTPA1 expression was associated with an increased number of M1 macrophages, CD8+ T cells, memory activated CD4+ T cells, regulatory T cells, as well as a reduced number of M2 macrophages. Our clinical data suggest that SFTPA1 may serve as a biomarker for predicting a favorable response to immunotherapy for patients with LUAD. Collectively, our study extends the expression profile and potential regulatory pathways of SFTPA1 and may provide a potential biomarker for establishing novel preventive and therapeutic strategies for lung adenocarcinoma.Keywords
Funding Information
- National Natural Science Foundation of China (81870026, 81602685, 81672992)
- Clinical Research Startup Program of Southern Medical University (LC2016PY006)
- Clinical Research Startup Program of Southern Medical University (LC2019ZD008)
- Clinical Research project of Nanfang Hospital, Southern Medical University (2018CR019, 2018CR021)
This publication has 42 references indexed in Scilit:
- Surfactant Protein A Suppresses Lung Cancer Progression by Regulating the Polarization of Tumor-Associated MacrophagesThe American Journal of Pathology, 2013
- Insights into the regulation of protein abundance from proteomic and transcriptomic analysesNature Reviews Genetics, 2012
- Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectorsProceedings of the National Academy of Sciences, 2012
- A ceRNA Hypothesis: The Rosetta Stone of a Hidden RNA Language?Cell, 2011
- Alveolar Surfactant Homeostasis and the Pathogenesis of Pulmonary DiseaseAnnual Review of Medicine, 2010
- CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinomaProceedings of the National Academy of Sciences, 2007
- High Number of Intraepithelial CD8+ Tumor-Infiltrating Lymphocytes Is Associated with the Absence of Lymph Node Metastases in Patients with Large Early-Stage Cervical CancerCancer Research, 2007
- Surfactant Protein A Gene Deletion and Prognostics for Patients with Stage I Non–Small Cell Lung CancerClinical Cancer Research, 2005
- The lung collectins, SP-A and SP-D, modulate pulmonary innate immunityMolecular Immunology, 2005
- Immunoregulatory functions of surfactant proteinsNature Reviews Immunology, 2005